Outlook Therapeutics is trading 6.36% up in pre-market at $0.50, with no clear catalyst identified. - No clear company-specific announcement dated October 15 was identified. Available news listings show no October 14 company headlines; the latest surfaced company news was the appointment of a chief commercial officer. - Major Asian markets were falling and Nasdaq futures were down, but this broader risk-off backdrop does not explain the pre-market gain.